These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23689224)

  • 1. Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
    Saba NS; Dang D; Saba J; Cao C; Janbain M; Maalouf B; Safah H
    Onkologie; 2013; 36(5):287-91. PubMed ID: 23689224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
    Castillo JJ; Reagan JL; Sikov WM; Winer ES
    Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
    Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
    Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
    Lipstein M; O'Connor O; Montanari F; Paoluzzi L; Bongero D; Bhagat G
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):E43-6. PubMed ID: 21856550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
    Dasanu CA; Bauer F; Codreanu I; Padmanabhan P; Rampurwala M
    Hematol Oncol; 2013 Sep; 31(3):164-6. PubMed ID: 22899491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib.
    Cencini E; Fabbri A; Guerrini S; Mazzei MA; Rossi V; Bocchia M
    Eur J Haematol; 2016 Jun; 96(6):650-654. PubMed ID: 26715026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
    J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-negative plasmablastic lymphoma: not in the mouth.
    Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin GA; Butera JN
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):185-9. PubMed ID: 21575922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmablastic lymphoma may occur as a high-grade transformation from plasmacytoma.
    Qing X; Sun N; Chang E; French S; Ji P; Yue C
    Exp Mol Pathol; 2011 Feb; 90(1):85-90. PubMed ID: 20969860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature.
    Bogusz AM; Seegmiller AC; Garcia R; Shang P; Ashfaq R; Chen W
    Am J Clin Pathol; 2009 Oct; 132(4):597-605. PubMed ID: 19762538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics.
    Hansra D; Montague N; Stefanovic A; Akunyili I; Harzand A; Natkunam Y; de la Ossa M; Byrne GE; Lossos IS
    Am J Clin Pathol; 2010 Nov; 134(5):710-9. PubMed ID: 20959653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmablastic lymphoma of the stomach in an HIV-negative patient.
    Hashimoto M; Inaguma S; Kasai K; Kuwabara K; Noda N; Hayakawa M; Fujino M; Ito M; Ikeda H
    Pathol Int; 2012 Nov; 62(11):763-70. PubMed ID: 23121609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
    Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
    Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.
    Elyamany G; Al Mussaed E; Alzahrani AM
    Adv Hematol; 2015; 2015():315289. PubMed ID: 26357515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.